Anti-(complement C5a) IgG4 chimeric monoclonal antibody ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 269 | 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 | 1 |
269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群
臨床試験数 : 24 / 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-003273-21-PL (EUCTR) | 09/11/2020 | 08/09/2020 | NA | Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum | Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody | InflaRx GmbH | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | United States;Poland |